Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run
Nagendran Sukumar executed the sale under a pre-established Rule 10b5-1 trading plan, retaining 936,410 shares worth $5.94 million.
Overview
Nagendran Sukumar, president and head of R&D at Taysha Gene Therapies, Inc. (NASDAQ:TSHA), sold 200,000 shares of common stock on July 10, 2026, for proceeds of $1.2 million, according to a recent SEC Form 4 filing.
Taysha Gene Therapies is a clinical-stage biotechnology company with a market capitalization of $1.60 billion, currently generating $7.50 million in TTM revenue while investing substantially in its gene therapy pipeline. The company leverages AAV vector technology as its core platform to develop differentiated therapeutic solutions for rare inherited CNS diseases, competing in a specialized segment of the biotechnology industry where clinical advancement and regulatory success are primary value drivers.
This sale ultimately seems like a standard scheduled cash-out given the underlying mechanics. The trade ran under a 10b5-1 plan Sukumar set more than a year ago, and even after selling, he holds 936,410 shares worth close to $6 million. When an R&D chief keeps a stake that size ahead of the company's biggest catalysts, it’s more likely that he's probably just diversifying and not doubting the science he's running.
Details
Operationally, Taysha last month reaffirmed FDA alignment on a BLA pathway for TSHA-102, its Rett syndrome gene therapy, including the pivotal REVEAL trial, which completed dosing of 17 patients last month and posted data showing early, durable treatment across all 12 pediatric, adolescent and adult patients. Meanwhile, the company’s $276.6 million cash balance funds operations into 2028, comfortably past those milestones.
For long-term investors, the insider sale is a sideshow, and instead, the REVEAL trial and the BLA submission timeline are the events that decide whether the stock's 149% run was justified. After all, the company is still a good example of the risks in biotech, having struggled in the years since reaching an all-time high above $30 per share and still down some 80%.
Source
Originally published at www.fool.com.